The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials

M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, Enver Akalin, N Alachkar, S Bagnasco, Y Bouatou, J U Becker, L D Cornell, J P Duong van Huyen, I W Gibson, Edward S Kraus, R B Mannon, M Naesens, V Nickeleit, P Nickerson, D L Segev, H K Singh, M Stegall, P Randhawa, L Racusen, K Solez, M Mengel, M Haas, A Loupy, C Lefaucheur, C Roufosse, D Glotz, D Seron, B J Nankivell, P F Halloran, R B Colvin, Enver Akalin, N Alachkar, S Bagnasco, Y Bouatou, J U Becker, L D Cornell, J P Duong van Huyen, I W Gibson, Edward S Kraus, R B Mannon, M Naesens, V Nickeleit, P Nickerson, D L Segev, H K Singh, M Stegall, P Randhawa, L Racusen, K Solez, M Mengel

Abstract

The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell-mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.

Keywords: classification systems: Banff classification; kidney transplantation/nephrology; molecular biology; pathology/histopathology; rejection; translational research/science.

© 2017 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.

Figures

Figure 1
Figure 1
Representative cases of chronic active T cell–mediated rejection, grades 1A (A, B) and 1B (C, D). Each biopsy specimen shows widespread interstitial inflammation (mainly lymphocytes in A and B; lymphocytes with plasma cells in C and D) with accompanying interstitial edema in areas of the cortex with interstitial fibrosis and tubular atrophy (i‐IFTA score 3). Both biopsy specimens also show tubulitis involving tubules with mild to moderate atrophic changes; this tubulitis is moderate (t2) in A and B and severe (t3) in C and D. There was also mild tubulitis (t1) in nonatrophic tubules in both biopsy specimens, and each specimen also had a total inflammation (ti) score of 2, although this cannot be determined from the photomicrographs. While both biopsy specimens show considerable edema associated with the inflammation, there is also interstitial fibrosis in these areas as is most evident from the darker staining areas of the interstitium in B and D. The yellow arrows indicate tubules with tubulitis; the tubules so indicated are the same tubules in the low‐power and corresponding high‐power photomicrographs (A, B; C, D). Jones methenamine silver stain; original magnification 100× (A, C) or 400× (B, D; scale bars in A and C indicate 50 µm)
Figure 2
Figure 2
Three renal allograft biopsies specimens showing inflammation in areas of interstitial fibrosis and tubular atrophy (i‐IFTA) with varying densities of interstitial fibrosis and degrees of interstitial inflammation, edema, and tubulitis, using 3 different histologic stains. The biopsy specimen in A‐C shows dense interstitial fibrosis but also widespread and focally heavy inflammation in the sclerotic interstitium (i‐IFTA 3) with tubulitis involving several mildly to moderately atrophic tubules, up to score t3 (arrow, B). The biopsy specimen in D‐F also shows dense interstitial fibrosis, but milder inflammation. Although the inflammation in D‐F is fairly diffuse, this was not true in other areas of cortex with fibrosis, and the i‐IFTA score on this biopsy was 2. In addition, there is only mild tubulitis (t1), and as such, this biopsy specimen did not meet criteria for chronic active T cell–mediated rejection. In the biopsy specimen in G‐I, the interstitial fibrosis is focally dense and focally less so with interstitial edema, as is most evident on the trichrome stain in I. There is more variable inflammation (overall i‐IFTA score was 2), although t2 tubulitis is evident in a mildly atrophic tubule (arrow, G). Hematoxylin and eosin (H&E; A, D, G), periodic acid–Schiff (PAS; B, E, H), and Masson trichrome (C, F, I) stains; original magnification 200× (all panels). The scale bar at the bottom right of each panel indicates 50 µm

References

    1. Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28‐41.
    1. Ekberg H, Tedesco‐Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562‐2575.
    1. O'Connell PJ, Kuypers DR, Mannon RB, et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction. Transplantation. 2017;101(7):1527‐1534.
    1. Stegall MD, Morris RE, Alloway RR, Mannon RB. Developing new immunosuppression for the next generation of transplant recipients: the path forward. Am J Transplant. 2016;16(4):1094‐1101.
    1. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long‐term outcomes in kidney transplantation. N Engl J Med. 2016;374(4):333‐343.
    1. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept‐based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535‐546.
    1. Hart Y, Sheftel H, Hausser J, et al. Inferring biological tasks using Pareto analysis of high‐dimensional data. Nat Methods. 2015;12(3):233‐235, 3 p following 5.
    1. Lefaucheur C, Gosset C, Rabant M, et al. T cell‐mediated rejection as a major determinant of inflammation in scarred areas in kidney transplant recipients. Am J Transplant. 2017. .
    1. Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant. 2009;9(8):1859‐1867.
    1. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant. 2010;10(9):2066‐2073.
    1. Nankivell B, Shingde M, Keung K, et al. The causes, significance, and consequences of inflammatory fibrosis in kidney transplantation: the Banff i‐IFTA lesion. Am J Transplant. 2018. .
    1. Venner JM, Famulski KS, Reeve J, Chang J, Halloran PF. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight. 2016;1(1):e85323.
    1. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant. 2013;13(3):634‐644.
    1. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions. Am J Transplant. 2014;14:272‐283.
    1. Reeve J, Sellares J, Mengel M, et al. Molecular diagnosis of T cell‐mediated rejection in human kidneys. Am J Transplant. 2013;13:645‐655.
    1. Halloran PF, Reeve J, Akalin E, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant. 2017;17:2851‐2862.
    1. Sellarés J, Reeve J, Loupy A, et al. Molecular diagnosis of antibody‐mediated rejection in human kidney transplants. Am J Transplant. 2013;13:971‐983.
    1. Halloran PF, Chang J, Famulski K, et al. Disappearance of T cell‐mediated rejection despite continued antibody‐mediated rejection in late kidney transplant recipients. J Am Soc Nephrol. 2015;26:1711‐1720.
    1. Loupy A, Lefaucheur C, Vernery D, et al. Molecular microscope strategy to improve risk stratification in early antibody‐mediated kidney allograft rejection. J Am Soc Nephrol. 2014;14:2267‐2277.
    1. Halloran PF, Venner JM, Famulski KS. Comprehensive analysis of transcript changes associated with allograft rejection: combining universal and selective features. Am J Transplant. 2017;17:1754‐1769.
    1. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753‐760.
    1. DeSerres S, Noel R, Cote I, et al. 2013 Banff criteria for chronic active antibody‐mediated rejection: assessment in a real life setting. Am J Transplant. 2016;16:1516‐1525.
    1. Gupta A, O'Broin P, Bao Y, et al. Clinical and molecular significance of microvascular inflammation in transplant kidney biopsies. Kidney Int. 2016;89:217‐225.
    1. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody‐mediated microcirculation inflammation in kidney transplants. Am J Transplant. 2012;12:1168‐1179.
    1. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor‐specific antibodies. Am J Transplant. 2013;13:485‐492.
    1. Collins AB, Schneeberger EE, Pascual MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10:2208‐2214.
    1. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in renal allograft recipients: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13:779‐787.
    1. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody‐dependent graft injury. J Am Soc Nephrol. 2002;13:1091‐1099.
    1. Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degration product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol. 2002;13:242‐251.
    1. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation. 2002;74:711‐717.
    1. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor‐specific antibodies: evidence for NK cell involvement in antibody‐mediated rejection. Am J Transplant. 2010;10:1812‐1822.
    1. Adam BA, Smith RN, Rosales IA, et al. Chronic antibody‐mediated rejection in nonhuman primate renal allografts: validation of human histological and molecular phenotypes. Am J Transplant. 2017;17:2841‐2850.
    1. Afzali B, Chapman E, Racape M, et al. Molecular assessment of microcirculation injury in formalin‐fixed cardiac allograft biopsies with antibody‐mediated rejection. Am J Transplant. 2017;17:496‐505.
    1. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplantated into cross‐match‐positive recipients. Transplantation. 2000;70:887‐895.
    1. Jordan SC, Quartel AW, Czer LSC, et al. Postransplant therapy using high‐dose human immunoglobulin (intravenous immunoglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanisms of action. Transplantation. 1998;66:800‐805.
    1. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO‐ and HLA‐incompatible renal allografts: correlation with histologic findings. Am J Transplant. 2006;6:1829‐1840.
    1. Reeve J, Bohmig GA, Eskandary F, et al. Assessing rejection‐related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017;2(12). .
    1. Halloran PF, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsy samples. Nat Rev Nephrol. 2016;12(9):534‐548.
    1. Aubert O, Loupy A, Hidalgo L, et al. Antibody‐mediated rejection due to preexisting versus de novo donor‐specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28(6):1912‐1923.
    1. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody‐mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15:1336‐1348.
    1. Hayde N, Broin PÓ, Bao Y, et al. Increased intragraft rejection‐associated gene transcripts in patients with donor‐specific antibodies and normal biopsies. Kidney Int. 2014;86(3):600‐609.
    1. Halloran PF, Pereira AB, Chang J, et al. Potential impact of microarray diagnosis of T cell‐mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant. 2013;13:2352‐2363.
    1. Venner JM, Famulski KS, Badr D, Hidalgo LG, Chang J, Halloran PF. Molecular landscape of T cell‐mediated rejection in human kidney transplants: prominence of CTLA4 and PD ligands. Am J Transplant. 2014;14:2565‐2576.

Source: PubMed

3
Abonneren